Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The appearance of genuine long-term institutional investors on the register would be a pivotal moment for ODX. As a poster above says, it is possible that this may be achieved through placings at some point - perhaps when further funding for expansion is required. The company remains thinly capitalised in the context of the development scenarios discussed daily here! However, if Richard Sneller is still a seller (I’d ignore all of the “charity” gloss that’s been applied to this) then his holding is another possibility for the company’s broker to get someone in, albeit one that would do nothing for the company in terms of funding. Perhaps a combination of the two? We’ll see. At a market cap of £100m+ the challenges for company advisers (particularly their broker) start to become more demanding. It’ll be interesting to see whether they stick or twist in this regard also.
Trickymatters
In what way i am deramping?
2 investor meeting in 8 weeks is wrong. imho
Sometimes, we don't call this things out and they get away with cr@p. Odx needs to produce. So far, its all fking promises.
Indeed... why another presentation.... they have absolutely zero obligation and could pick and choose the timing of this to suit them. Just so happens to be around the time we expect news on UK RTC. And launch of Mologic Antibody tests. And completion of scale up. If news was 2 weeks away, why not hold the presentation for 2 weeks?
When you have 7-8 million shares remaining, simply offloading another 500,000 shares is called "A massive sell off" by some.
iPhone trade, you were mindless ramping this morning. Now you are mindless deramping. We can see you coming from round corners. Sigh.
A massive sell off this morning. Look at the trades.
It would not have happened if they decided to update via RNS. A general update RNS
I was in the investor presentation 2 months ago and literally, nothing has changed since.
Is the presentation going to promise jam tomorrow ? We're meant to be at the business end. You should be out there selling.
I do agree that we need some concrete update / sales update as the market is never keen on uncertainty, however the idea that we would not fill our capacity in the middle of a global pandemic, going into the winter with a second wave upon us is highly unlikely.
Thanks - didnt register the increase from 500k to 1 million. Is this with furutre additional production equipemnt purchase ie - current expansion gets us to 500k and potntial future expansion gets us to 1m
Although the 2 million would be both Lateral flow and Elisa. Not sure if it would mean 2 million of any sort - not very clear
I get that we have not yet seen RTC sales for lateral flow test but would like to see the Elisa test sales to India (and wonder why there are no UK sales)
But also CD4 sales
From the Investor meets company presentation link to a screenshot of the slide below:
- £1.1m | COVID-19 –ELISA Testing: 275k tests per week to 1m tests per week
- £3.0m | COVID-19 –LFT: 100k tests per week to 500k tests per week (£1.1m) extended to 1.0m tests per week (£1.9m)
- £0.4m | VISITECT® CD4Margin Improvement
- £2.7m | Expand Lateral Flow Product Portfolio
- £1.0m | Repayment of Overdraft Facility
- £2.3m | Working Capital estimate
-----------
- £10.5m | Total
Link: https://imgur.com/a/nHmLEdz
Im very pro Omega and although i would like it to be true - where did this 2 million a week figure come from - i thought it was 400k which now looks to be 500k
@showmethemoneysh We raised cash in June to ramp up to 2m tests/week
As long as institutions are negotiating placing options to get onboard. We have all the info from Colin around ramping up capacity so does anyone expect Colin to explain how many of our tests we have stockpiled and for what purpose. Why ramp up manufacturing, employ 50 odd more staff without concrete assurances that orders will come...
going back a few weeks to a post by someone I believe (and hope) that the delays are based on the fact we don't have the test number we need to satisfy nationwide rollout. Any idea what these numbers might need to be to start - 10mil?
500k capacity won't be enough so how are we going to ramp this up - extend further and with what cash? Look abroad?
One of ODX’s major investors knows the TPI team well and suggested that they might want to tell their story to a wider audience of investors (i.e. TPI’s client base of high net worth individuals and other investors).
I think we will be attracting a lot of interest, including Institutional Investors.
The other plus point is we could attract some institutional interest. More so than ever now with a market cap way over a 100 milion.
I not sure of the significance of this,but avacta are a client of turner hope.